These findings collectively demonstrated that HAQ/223Ra@HNPs, when combined with anti-PD-L1 therapy, effectively inhibited both primary and metastatic tumor growth by enhancing systemic immune responses and promoting tumor-specific T cell activation. Here, CD274 is linked to metastatic neoplasm.